InfuTronix recalls its Nimbus infusion pump systems due to multiple potential failure modes that may include battery failure, upstream blockage (occlusion), and system errors, among other problems.
FDA grants fast track designation to Compass’ CTX-009 that is in a Phase 2 study with paclitaxel to treat some biliary tract tumors.
InfuTronix recalls its Nimbus infusion pump systems due to multiple potential failure modes that may include battery failure, upstream blockage (occlusion), and system errors, among other problems.
FDA grants fast track designation to Compass’ CTX-009 that is in a Phase 2 study with paclitaxel to treat some biliary tract tumors.
FDA publishes a draft guidance to help sponsors expand eligibility for cancer drug clinical trials in terms of washout periods and concomitant medication exclusions.
Federal Register notice: FDA announces that OMB has approved an information collection entitled “Electronic Records: Electronic Signatures.”
